Finally, diagnosis remains a challenge in IBD disease management, and our findings suggest that TRIM40 could represent a potential biomarker for use in the diagnosis of both UC and CD using rectum tissue biopsies as well as a therapeutic target to limit IBD initiation and development. This evidence concerns the gene TRIM40 and inflammatory bowel disease.